Related Experiment Video
Updated: May 14, 2026
11:36
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Acetyl-L-carnitine in hepatic encephalopathy
1International Ph.D. Program in Neuropharmacology, University of Catania, Catania, Italy. m.malaguarnera@email.it
Metabolic Brain Disease
|February 8, 2013
Summary
Hepatic encephalopathy (HE) symptoms may improve with Acetyl-L-carnitine. This compound reduces ammonia levels, potentially alleviating cognitive and physical impairments in HE patients.
Area of Science:
- Neuroscience
- Gastroenterology
- Biochemistry
Background:
- Hepatic encephalopathy (HE) is a common complication of hepatic cirrhosis.
- Clinical diagnosis involves impaired mental status and neuromotor function.
- Elevated ammonia and inflammation are thought to cause brain swelling and HE symptoms.
Purpose of the Study:
- To explain the toxic effects of ammonia in HE.
- To evaluate the clinical benefits of Acetyl-L-carnitine (ALC) in managing HE.
Main Methods:
- Review of existing literature on HE pathogenesis and ALC.
- Analysis of ALC's biochemical mechanisms, including ureagenesis.
- Evaluation of studies reporting ALC's effects on neuropsychological functions and quality of life.
Main Results:
- Acetyl-L-carnitine (ALC) administration aids in recovering neuropsychological functions.
- ALC induces ureagenesis, decreasing blood and brain ammonia levels.
- ALC treatment improves cognitive function, reduces fatigue and depression, and enhances quality of life.
Conclusions:
- Acetyl-L-carnitine shows potential clinical benefits for hepatic encephalopathy.
- ALC's ability to reduce ammonia levels is a key mechanism for its therapeutic effects.
- Further research may solidify ALC's role in HE management.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Phase II Reactions: Acetylation Reactions
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...